Lupin CEO On ProAir Generic Site Transfer, Digital Plans
Amazon Entry Not A Near-term Worry
Executive Summary
Lupin CEO Vinita Gupta shares plans to shift manufacture of albuterol and some other products to its US facilities, with a rollout of a generic to Teva’s ProAir expected soon. Enthused by Lupin’s first biosimilar introduction In Europe with etanercept and looking to up the company’s digital game, the executive says Amazon’s entry into India’s e-pharmacy space is not a near-term worry
You may also be interested in...
Lupin's Glumetza Settlement Costs But Spiriva Offers Hope
Lupin’s Q2 was a tale of three generics settlements – on Glumetza, which is still a commercial win despite the quarter-billion dollar outgo so far, on Spiriva, which will likely lead to happy tidings next fiscal year, and on Revlimid, on which the company has yet to make up its mind.
Lupin's Glumetza Settlement Costs But Spiriva Offers Hope
Lupin’s Q2 was a tale of three generics settlements – on Glumetza, which is still a commercial win despite the quarter-billion dollar outgo so far, on Spiriva, which will likely lead to happy tidings next fiscal year, and on Revlimid, on which the company has yet to make up its mind.
Lupin Expects Respiratory Ramp Up From Fiscal '22
After launching albuterol, India's Lupin is seeking to expand its presence in the respiratory market. With generic Fostair set for a European launch in fiscal 2022 and Spiriva for a US introduction the following fiscal year, the company is counting on the portfolio to deliver growth from the coming financial year.